RCS - Belluscura PLC - New Wound Care Joint Venture

BelluscuraAnnouncement

03/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241203:nRSC4983Oa&default-theme=true

RNS Number : 4983O  Belluscura PLC  03 December 2024

3 December 2024

 

BELLUSCURA PLC

("Belluscura" or the "Company" or "Group")

 

New Wound Care Joint Venture

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces that the
Company has entered into a product development joint venture with its research
partner Separation Design Group and a major medical device company to explore
the use of oxygen-based wound care solutions.

 

Belluscura will serve as the original equipment manufacturer (OEM), while the
major medical device company will fund product development, clinical trials,
and distribution upon regulatory approval, with an initial clinical study
scheduled to begin in early Q2 2025, outside the United States.

 

The joint venture will focus on innovative oxygen-based solutions for the
wound care market, leveraging Belluscura's expertise in oxygen technology. In
particular, it will focus on developments in continuously diffused oxygen
(CDO) therapy, a topical oxygen delivery method designed to accelerate wound
healing by providing pure oxygen directly to the wound. CDO therapy has
demonstrated promise in treating chronic or hard-to-heal wounds, including
diabetic foot ulcers.

 

The wound care market, valued at $22.5 billion in 2023, is projected to grow
at a robust 5.9% CAGR through to 2032, according to a Global Markets Insights
report published in 2023(1), and Belluscura's technology and expertise
positions it well to capitalise on this significant market opportunity.

 

Commenting, Bob Rauker, Chief Executive said:

 

"Our joint venture with Separation Design Group demonstrates the potential of
leveraging our oxygen-based technology across broader therapeutic applications
and healthcare challenges, such as addressing an unmet need in the
hard-to-heal wounds market, which is valued at over $22 billion today and
growing.

 

"Partnering with a globally recognized medical device company enables us to
explore the development and commercialization of this innovative wound care
solution by combining our oxygen enrichment technology and expertise with
their resources and distribution capabilities."

 

-Ends-

(1) Wound Care Market - Product (Advanced Wound Dressing, Surgical Wound Care,
Traditional Wound Care, WoundTherapy Devices, Wound Care Biologics),
Application (Chronic, Acute), End use - Global Forecast, 2023-2032

For further information please contact:

 

 Belluscura plc                             Tel: +44 (0)20 3128 8100
 Adam Reynolds, Chairman

 Robert Rauker, CEO

 Simon Neicheril, Chief Financial Officer

 SPARK Advisory Partners Limited            Tel: +44 (0)20 3368 3550

 Nominated Adviser
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited                    Tel: +44 (0)20 3903 7715

 Broker
 Russell Cook / Nicholas Chambers

 MHP                                        Tel: +44 (0)20 3128 8100

 Financial PR & Investor Relations          email: Belluscura@mhpgroup.com (about:blank)
 Katie Hunt/Matthew Taylor

 

About Belluscura plc (https://ir.belluscura.com/)

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFSFFWEELSEIE